Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into a ...
Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026: OXB (LSE: OXB), a ...
Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research ...
Applied Biopharm Consulting Ltd has been awarded an Intellectual Property (IP) Start Grant from the Local Enterprise Office ...
Viral vector gene therapy represents a rapidly advancing field at the intersection of molecular medicine, biotechnology, and clinical translation. Viral ...
The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...
CytoNiche’s 3D FloTrix™ platform won the Emerging Bioprocessing Supplier – Downstream award at ABEA 2026, recognising ...
New open-source library lets developers give any AI agent long-term memory that humans can read, edit, and trust-extracted from OpenClaw's viral memory system and powered by the Milvus vector database ...
Belief BioMed ("BBM") and Grand Life Sciences Group Co., Ltd. ("Grand Life Sciences") today announced an exclusive collaboration agreement. Under the agreement, Belief BioMed will grant Grand Life ...
Belief BioMed (BBM) today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially ...
BioAnalysis launches BASIS 2.0, its next-gen GMP-compliant AUC software for gene therapy. Higher throughput, one-click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results